Biologic Patent Protection: When Biosimilars Can Enter the U.S. Market
Biologic patent protection in the U.S. delays biosimilar entry for up to 12 years, keeping drug prices high. Learn how the BPCIA, patent thickets, and development costs block competition - and what it means for patients.
- 0